We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Labcorp Q1 Earnings Preview: Diagnostics Arm Likely to Drive Growth
Read MoreHide Full Article
Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is slated to report its first-quarter 2025 results on April 29, before the opening bell.
The renowned laboratory service provider reported adjusted earnings of $3.45 in the last reported quarter, topping the Zacks Consensus Estimate by 1.47%. Labcorp surpassed estimates in each of the trailing four quarters, the average surprise being 3.16%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
LH’s Q1 Estimates
The Zacks Consensus Estimate for Labcorp’s first-quarter 2025 revenues is pegged at $3.42 billion. This suggests a 7.6% rise from the year-ago reported figure.
The Zacks Consensus Estimate for its first-quarter 2025 EPS is expected to improve by 1.6% to $3.74.
Estimate Revision Trend Ahead of Labcorp’s Q1 Earnings
Estimates for Labcorp’s first-quarter earnings have dropped 1 cent to $3.74 in the past seven days.
Here’s a brief overview of the company’s progress ahead of this announcement.
Factors at Play
Diagnostics Laboratories (Dx)
The segment likely continued the strong momentum of last year, supported by both organic growth and the strength of acquisitions. Labcorp’s string of partnerships with hospitals, health systems and regional local laboratories is expected to have been instrumental to this growth. As stated earlier, during the first quarter of 2025, the company enhanced access to its diagnostic capabilities through collaboration with Inspira Health. It has also expanded the Raritan, NJ, laboratory.
Last year, Labcorp acquired select assets and molecular testing locations of Lab Works in Alabama, and completed the purchase of select outreach laboratory services for Ballad Health in the Appalachian region. Its acquisition of BioReference Health's laboratory testing businesses expanded its clinical diagnostics footprint beyond New York and New Jersey. These developments are expected to have strongly boosted Labcorp’s revenues in the to-be-reported quarter.
Furthermore, the company might have continued to make notable advances in science, technology and innovations to lead in important therapeutic areas during the to-be-reported quarter. The Invitae acquisition is expected to have bolstered Labcorp’s genetic testing capabilities, particularly in oncology and select rare diseases. In February 2025, it announced the clinical availability of its liquid biopsy test, Labcorp Plasma Complete. Among other recent developments, the company launched a multiple sclerosis monitoring profile to monitor neurofilament light chain serum and GFAP values in multiple sclerosis patients.
Labcorp’s first companion diagnostic assay is also now available to identify gastric cancer patients eligible to receive targeted treatment with VYLOY. Additionally, the Labcorp OnDemand platform, which offers a wide range of consumer-initiated wellness tests, is expected to have significantly contributed to the company’s top-line in the first quarter of 2025.
The Zacks Consensus Estimate indicates an 8.4% year-over-year increase in the Dx segment’s revenues in the to-be-reported quarter.
Biopharma Laboratory Services (BLS)
The segment is likely to have benefited from the ongoing strength in the Central Laboratories business, its largest component in the first quarter. Labcorp’s Global Trial Connect suite of digital and data solutions is expected to have seen strong customer adoption, with new enhancements such as improved site workflow efficiency and deeper insights through continued collaboration across sponsors and sites.
Similar to the fourth quarter, the company likely saw strong uptake of Labcorp Diagnostics Assistant by health system clients and their physicians, helping bring together lab result data, clinical guidelines and EHR data to inform clinical decisions at the point of care. Additionally, the Early Development unit is expected to have contributed to the 2025 first-quarter revenues, led by improved gross order bookings and cancellations.
According to the Zacks Consensus Estimate, revenues in the BLS segment are likely to improve 7.6% year over year.
From an operational standpoint, we expect both the segments’ margins to have improved in first-quarter 2025, aiding the overall enterprise margin. In 2024, Labcorp achieved its targeted annual savings of $100-$125 million through its Launchpad initiative, the synergies of which are likely to have aided in managing costs. The Zacks Consensus Estimate implies a 4.3% increase in the adjusted operating income for the Dx business, while the same for the BLS arm indicates a 9% improvement year over year.
Earnings Whispers for Labcorp
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
LH’s Earnings ESP: Labcorp has an Earnings ESP of -0.87%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.41%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 61% from the year-ago quarter figure.
Veeva Systems (VEEV - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2026 results soon.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.92%. The Zacks Consensus Estimate for VEEV’s fiscal first-quarter EPS is expected to surge 16% from the year-ago reported figure.
Hims & Hers Health (HIMS - Free Report) has an Earnings ESP of +115.69% and a Zacks Rank #2. The company is expected to release first-quarter 2025 results soon.
HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 40.42%. The Zacks Consensus Estimate for Hims & Hers Health’s first-quarter EPS is expected to increase by 180% from the year-ago quarter figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Labcorp Q1 Earnings Preview: Diagnostics Arm Likely to Drive Growth
Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is slated to report its first-quarter 2025 results on April 29, before the opening bell.
The renowned laboratory service provider reported adjusted earnings of $3.45 in the last reported quarter, topping the Zacks Consensus Estimate by 1.47%. Labcorp surpassed estimates in each of the trailing four quarters, the average surprise being 3.16%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
LH’s Q1 Estimates
The Zacks Consensus Estimate for Labcorp’s first-quarter 2025 revenues is pegged at $3.42 billion. This suggests a 7.6% rise from the year-ago reported figure.
The Zacks Consensus Estimate for its first-quarter 2025 EPS is expected to improve by 1.6% to $3.74.
Estimate Revision Trend Ahead of Labcorp’s Q1 Earnings
Estimates for Labcorp’s first-quarter earnings have dropped 1 cent to $3.74 in the past seven days.
Here’s a brief overview of the company’s progress ahead of this announcement.
Factors at Play
Diagnostics Laboratories (Dx)
The segment likely continued the strong momentum of last year, supported by both organic growth and the strength of acquisitions. Labcorp’s string of partnerships with hospitals, health systems and regional local laboratories is expected to have been instrumental to this growth. As stated earlier, during the first quarter of 2025, the company enhanced access to its diagnostic capabilities through collaboration with Inspira Health. It has also expanded the Raritan, NJ, laboratory.
Last year, Labcorp acquired select assets and molecular testing locations of Lab Works in Alabama, and completed the purchase of select outreach laboratory services for Ballad Health in the Appalachian region. Its acquisition of BioReference Health's laboratory testing businesses expanded its clinical diagnostics footprint beyond New York and New Jersey. These developments are expected to have strongly boosted Labcorp’s revenues in the to-be-reported quarter.
Labcorp Price and EPS Surprise
Labcorp price-eps-surprise | Labcorp Quote
Furthermore, the company might have continued to make notable advances in science, technology and innovations to lead in important therapeutic areas during the to-be-reported quarter. The Invitae acquisition is expected to have bolstered Labcorp’s genetic testing capabilities, particularly in oncology and select rare diseases. In February 2025, it announced the clinical availability of its liquid biopsy test, Labcorp Plasma Complete. Among other recent developments, the company launched a multiple sclerosis monitoring profile to monitor neurofilament light chain serum and GFAP values in multiple sclerosis patients.
Labcorp’s first companion diagnostic assay is also now available to identify gastric cancer patients eligible to receive targeted treatment with VYLOY. Additionally, the Labcorp OnDemand platform, which offers a wide range of consumer-initiated wellness tests, is expected to have significantly contributed to the company’s top-line in the first quarter of 2025.
The Zacks Consensus Estimate indicates an 8.4% year-over-year increase in the Dx segment’s revenues in the to-be-reported quarter.
Biopharma Laboratory Services (BLS)
The segment is likely to have benefited from the ongoing strength in the Central Laboratories business, its largest component in the first quarter. Labcorp’s Global Trial Connect suite of digital and data solutions is expected to have seen strong customer adoption, with new enhancements such as improved site workflow efficiency and deeper insights through continued collaboration across sponsors and sites.
Similar to the fourth quarter, the company likely saw strong uptake of Labcorp Diagnostics Assistant by health system clients and their physicians, helping bring together lab result data, clinical guidelines and EHR data to inform clinical decisions at the point of care. Additionally, the Early Development unit is expected to have contributed to the 2025 first-quarter revenues, led by improved gross order bookings and cancellations.
According to the Zacks Consensus Estimate, revenues in the BLS segment are likely to improve 7.6% year over year.
From an operational standpoint, we expect both the segments’ margins to have improved in first-quarter 2025, aiding the overall enterprise margin. In 2024, Labcorp achieved its targeted annual savings of $100-$125 million through its Launchpad initiative, the synergies of which are likely to have aided in managing costs. The Zacks Consensus Estimate implies a 4.3% increase in the adjusted operating income for the Dx business, while the same for the BLS arm indicates a 9% improvement year over year.
Earnings Whispers for Labcorp
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
LH’s Earnings ESP: Labcorp has an Earnings ESP of -0.87%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
LH’s Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Masimo (MASI - Free Report) has an Earnings ESP of +0.64% and a Zacks Rank #1. The company is expected to release first-quarter 2025 results soon. You can see the complete list of today’s Zacks #1 Rank stocks here.
MASI’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 14.41%. The Zacks Consensus Estimate for the company’s first-quarter EPS is expected to increase 61% from the year-ago quarter figure.
Veeva Systems (VEEV - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2026 results soon.
The company’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.92%. The Zacks Consensus Estimate for VEEV’s fiscal first-quarter EPS is expected to surge 16% from the year-ago reported figure.
Hims & Hers Health (HIMS - Free Report) has an Earnings ESP of +115.69% and a Zacks Rank #2. The company is expected to release first-quarter 2025 results soon.
HIMS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 40.42%. The Zacks Consensus Estimate for Hims & Hers Health’s first-quarter EPS is expected to increase by 180% from the year-ago quarter figure.